- In January 2024, STEMCELL Technologies expanded its portfolio with the acquisition of Propagenix Inc., a strategic move to further its growth in the scientific and clinical research sectors. This merger is expected to enhance the company’s capabilities in advancing stem cell technologies, enabling new breakthroughs in disease treatment. By combining expertise, the acquisition aims to accelerate innovation in both laboratory research and clinical applications, contributing to the development of more effective therapies for various medical conditions
- In September 2024, the Allen Institute for Cell Science and the New York Stem Cell Foundation (NYSCF) announced a groundbreaking collaboration to address a significant challenge in disease research. By combining the Allen Institute’s advanced structural tags with NYSCF's diverse collection of ethnically representative stem cell lines, the partnership aims to create more inclusive and accurate cellular models. This integration will enhance research capabilities and promote a deeper understanding of diseases across different populations
- In September 2023, the Abu Dhabi government announced a series of initiatives focused on the utilization of human stem cells and tissues to drive advancements in personalized medicine. This initiative includes the creation of a biobank designed to support the development of customized treatment plans based on human stem cells and tissues. The project aims to accelerate research and improve the delivery of precision healthcare through innovative therapies and protocols, placing Abu Dhabi at the forefront of stem cell-based medical advancements
- In September 2023, researchers in Israel made a groundbreaking achievement by successfully creating a model of a human embryo in the laboratory using stem cells, bypassing the need for sperm, eggs, or a womb. This significant advancement offers a rare and valuable insight into the early stages of human embryonic development. The model could provide essential data for stem cell research, offering a deeper understanding of developmental processes and the potential for future advancements in regenerative medicine and disease modeling
- In February 2023, Garuda Therapeutics announced it had secured an additional USD 62 million in funding, supplementing its initial USD 72 million investment. The company, which is focused on the development of stem cell-based therapies for a range of diseases, used the new funding to expand its research efforts. Garuda increased its target list of diseases from 70 to 120, underscoring its commitment to exploring the therapeutic potential of stem cells in addressing a broader spectrum of medical conditions and advancing innovative treatment options
